The FDA has announced an "ultra-fast" review of three psychedelic drugs aimed at treating mental health conditions including depression, signaling a significant commitment from the Trump administration to this experimental therapeutic approach.
President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to accelerate access and ease restrictions on psychedelics, a class of hallucinogenic drugs that remain illegal under federal law.
